| Structural polymorphism at LCR and its role in beta-globin gene regulation S Kukreti, H Kaur, M Kaushik, A Bansal, S Saxena, S Kaushik, R Kukreti Biochimie 92 (9), 1199-1206, 2010 | 102 | 2010 |
| Association studies of catechol-O-methyltransferase (COMT) gene with schizophrenia and response to antipsychotic treatment M Gupta, P Bhatnagar, S Grover, H Kaur, R Baghel, Y Bhasin, C Chauhan, ... Future Medicine Ltd 10 (3), 385-397, 2009 | 97 | 2009 |
| Gender specific association of RAS gene polymorphism with essential hypertension: a case-control study K Dhanachandra Singh, A Jajodia, H Kaur, R Kukreti, M Karthikeyan BioMed Research International 2014, 2014 | 85 | 2014 |
| Catechol-O-methyltransferase Val158Met polymorphism and clinical response to antipsychotic treatment in schizophrenia and schizo-affective disorder patients: a meta-analysis E Huang, CC Zai, A Lisoway, M Maciukiewicz, D Felsky, AK Tiwari, ... International journal of neuropsychopharmacology 19 (5), pyv132, 2016 | 64 | 2016 |
| Absence of a general association between ABCB1 genetic variants and response to antiepileptic drugs in epilepsy patients S Grover, K Bala, S Sharma, M Gourie-Devi, R Baghel, H Kaur, M Gupta, ... Biochimie 92 (9), 1207-1212, 2010 | 58 | 2010 |
| Genetic profile of patients with epilepsy on first-line antiepileptic drugs and potential directions for personalized treatment S Grover, M Gourie-Devi, R Baghel, S Sharma, K Bala, M Gupta, ... Pharmacogenomics 11 (7), 927-941, 2010 | 52 | 2010 |
| Genetic polymorphisms in sex hormone metabolizing genes and drug response in women with epilepsy S Grover, P Talwar, M Gourie-Devi, M Gupta, K Bala, S Sharma, R Baghel, ... Pharmacogenomics 11 (11), 1525-1534, 2010 | 36 | 2010 |
| Evidence for schizophrenia susceptibility alleles in the Indian population: an association of neurodevelopmental genes in case–control and familial samples A Jajodia, H Kaur, K Kumari, M Gupta, R Baghel, A Srivastava, M Sood, ... Schizophrenia research 162 (1-3), 112-117, 2015 | 35 | 2015 |
| Diverse facets of COMT: from a plausible predictive marker to a potential drug target for schizophrenia M Gupta, H Kaur, A Jajodia, S Jain, K Satyamoorthy, M Mukerji, J Thirthalli, ... Current Molecular Medicine 11 (9), 732-743, 2011 | 29 | 2011 |
| Cerebrospinal fluid (CSF) biomarkers of iron status are associated with CSF viral load, antiretroviral therapy, and demographic factors in HIV-infected adults SM Patton, Q Wang, T Hulgan, JR Connor, P Jia, Z Zhao, SL Letendre, ... Fluids and Barriers of the CNS 14, 1-16, 2017 | 25 | 2017 |
| Association of serotonin transporter (SLC6A4) & receptor (5HTR1A, 5HTR2A) polymorphisms with response to treatment with escitalopram in patients with major depressive disorder … A Basu, RK Chadda, M Sood, H Kaur, R Kukreti Indian Journal of Medical Research 142 (1), 40-45, 2015 | 25 | 2015 |
| Synergistic association of PI4KA and GRM3 genetic polymorphisms with poor antipsychotic response in south Indian schizophrenia patients with low severity of … H Kaur, A Jajodia, S Grover, R Baghel, S Jain, R Kukreti American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 165 …, 2014 | 24 | 2014 |
| Evaluation of genetic association of neurodevelopment and neuroimmunological genes with antipsychotic treatment response in schizophrenia in Indian populations. A Jajodia, H Kaur, K Kumari, N Kanojia, M Gupta, R Baghel, M Sood, ... Molecular Genetics and Genomics Medicine 4 (1), 18-27, 2015 | 23 | 2015 |
| Systems approach to identify common genes and pathways associated with response to selective serotonin reuptake inhibitors and major depression risk A Srivastava, P Singh, H Gupta, H Kaur, N Kanojia, D Guin, M Sood, ... International journal of molecular sciences 20 (8), 1993, 2019 | 20 | 2019 |
| Genetic variations of PIP4K2A confer vulnerability to poor antipsychotic response in severely ill schizophrenia patients H Kaur, A Jajodia, S Grover, R Baghel, M Gupta, S Jain, R Kukreti PLoS One 9 (7), e102556, 2014 | 20 | 2014 |
| Identifying a predictive model for response to atypical antipsychotic monotherapy treatment in south Indian schizophrenia patients M Gupta, NS Moily, H Kaur, A Jajodia, S Jain, R Kukreti Genomics 102 (2), 131-135, 2013 | 20 | 2013 |
| Genetic studies indicate a potential target 5‐HTR3B for Drug Therapy in Schizophrenia Patients M Gupta, S Jain, NS Moily, H Kaur, A Jajodia, M Purushottam, R Kukreti American Journal of Medical Genetics-Neuropsych Genetics Part B 159 (8), 1006, 2012 | 16 | 2012 |
| A preliminary association study between serotonin transporter (5-HTTLPR), receptor polymorphisms (5-HTR1A, 5-HTR2A) and depression symptom-clusters in a north Indian population … A Basu, RK Chadda, M Sood, H Kaur, R Kukreti Asian Journal of Psychiatry 43, 184-188, 2019 | 15 | 2019 |
| Pharmacogenomics and treatment for dementia induced by Alzheimer’s disease M Gupta, H Kaur, S Grover, R Kukreti Future Medicine Ltd 9 (7), 895-903, 2008 | 14 | 2008 |
| Evaluating the Role of Genetic Variants on first‐line antiepileptic drug response in North India: Significance of SCN1A and GABRA1 Gene Variants in Phenytoin … R Baghel, S Grover, H Kaur, A Jajodia, C Rawat, A Srivastava, ... CNS neuroscience & therapeutics 22 (9), 740-757, 2016 | 13 | 2016 |
